Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?

Wednesday, February 27, 2019
Presented by: 
Eric Henry

Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss: 

  • The potential impact of biosimilars at this tipping point in the pharmaceutical industry 
  • FDA-required suffixes and standards for biosimilars naming 
  • Prescription workflow best practices for small and large molecule biosimilars 
  • Issues raised by retrospective naming and products without suffixes 

The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products.

You may also like:

Blog Post

In August, Wolters Kluwer hosted Dr. Jeanne Sun, PharmD, JD, of USP in a webinar titled “

View Blog Post
Blog Post

Developments in healthcare technology and informatics have played an important role in the advancement of the field of pharmacy and the role of pharmacists. In the recent article

View Blog Post
Blog Post

Results released last month from the 2019 J.D. Power  U.S. Pharmacy Satisfaction Study showed that patients enjoy visiting brick-and-mort...

View Blog Post

Filter by Type

Sign up to receive the latest news and information!

Sign Up